Published in J Immunol on November 01, 2005
Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology (2006) 1.64
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A (2010) 1.39
HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol (2011) 1.26
How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med (2006) 1.20
Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol (2013) 1.14
Determinants of protection among HIV‐exposed seronegative persons: an overview. J Infect Dis (2010) 1.13
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis (2011) 1.03
Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J Virol (2011) 1.02
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol (2010) 1.02
HIV-1 induced bystander apoptosis. Viruses (2012) 1.01
CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr (2012) 1.01
FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging (2008) 1.00
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis (2010) 0.99
Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. PLoS One (2012) 0.96
Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates. J Infect Dis (2011) 0.96
Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity (2017) 0.91
Cytomegalovirus upregulates expression of CCR5 in central memory cord blood mononuclear cells, which may facilitate in utero HIV type 1 transmission. J Infect Dis (2014) 0.91
Immune quiescence: a model of protection against HIV infection. Retrovirology (2013) 0.91
HTLV-1 in rural Guinea-Bissau: prevalence, incidence and a continued association with HIV between 1990 and 2007. Retrovirology (2010) 0.89
Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells. PLoS One (2013) 0.88
Marked differences in CCR5 expression and activation levels in two South African populations. Immunology (2012) 0.86
Reduced cellular susceptibility to in vitro HIV infection is associated with CD4+ T cell quiescence. PLoS One (2012) 0.84
Helminth-associated systemic immune activation and HIV co-receptor expression: response to albendazole/praziquantel treatment. PLoS Negl Trop Dis (2014) 0.84
Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol (2013) 0.84
Distinct patterns of Bcl-2 expression occur in R5- and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo. AIDS Res Hum Retroviruses (2014) 0.82
The intensity of immune activation is linked to the level of CCR5 expression in human immunodeficiency virus type 1-infected persons. Immunology (2012) 0.80
The oral mucosa immune environment and oral transmission of HIV/SIV. Immunol Rev (2013) 0.79
A dendrite in every pie: myeloid dendritic cells in HIV and SIV infection. Virulence (2012) 0.79
HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism. PLoS One (2012) 0.79
Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol (2014) 0.78
Increased frequency of circulating Tc22/Th22 cells and polyfunctional CD38(-) T cells in HIV-exposed uninfected subjects. Sci Rep (2015) 0.78
Mucosal correlates of protection in HIV-1-exposed sero-negative persons. Am J Reprod Immunol (2014) 0.78
Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum. J Acquir Immune Defic Syndr (2016) 0.77
INTIMATE PARTNER VIOLENCE IS ASSOCIATED WITH INCREASED CD4(+) T-CELL ACTIVATION AMONG HIV-NEGATIVE HIGH-RISK WOMEN. Pathog Immun (2016) 0.77
Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals. AIDS Res Hum Retroviruses (2008) 0.76
HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol (2015) 0.76
Social and immunological differences among uninfected Brazilians exposed or unexposed to human immunodeficiency virus-infected partners. Mem Inst Oswaldo Cruz (2014) 0.76
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. J Infect Dis (2014) 0.76
Can an immune-regulatory vaccine prevent HIV infection? Expert Rev Anti Infect Ther (2012) 0.75
Natural killer cell and T-cell subset distributions and activation influence susceptibility to perinatal HIV-1 infection. AIDS (2014) 0.75
A transcriptome-based model of central memory CD4 T cell death in HIV infection. BMC Genomics (2016) 0.75
BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial. JCI Insight (2017) 0.75
Azasugar-containing phosphorothioate oligonucleotide (AZPSON) DBM-2198 inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking HIV-1 gp120 without affecting the V3 region. Mol Cells (2015) 0.75
Study of T cell subsets and IL-7 protein expression in HIV-1-infected patients after 7 years HAART. Eur J Med Res (2011) 0.75
Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis (2015) 0.75
Myristoylation: An Important Protein Modification in the Immune Response. Front Immunol (2017) 0.75
Host and Viral Factors in HIV-Mediated Bystander Apoptosis. Viruses (2017) 0.75
CCR5 expression, haplotype and immune activation in protection from infection in HIV-exposed uninfected individuals in HIV serodiscordant relationships. Immunology (2017) 0.75
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity (2012) 2.41
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol (2009) 2.31
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS (2009) 2.07
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Multiparameter evaluation of human thymic function: interpretations and caveats. Clin Immunol (2005) 1.97
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood (2002) 1.73
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend (2005) 1.69
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc Natl Acad Sci U S A (2008) 1.62
Unravelling the impact of ethnicity on health in Europe: the HELIUS study. BMC Public Health (2013) 1.59
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis (2014) 1.59
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood (2011) 1.53
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis (2014) 1.50
Thymic output: a bad TREC record. Nat Immunol (2003) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS (2009) 1.48
The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41
Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol (2005) 1.39
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. AIDS (2007) 1.38
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol (2002) 1.36
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood (2002) 1.31
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (2011) 1.31
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS (2009) 1.31
Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett (2005) 1.28
Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS (2002) 1.28
Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. Sex Transm Dis (2008) 1.26
Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat Protoc (2008) 1.26
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med (2010) 1.26
CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 1.26
High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. Sex Transm Dis (2012) 1.25
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis (2013) 1.23
Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood (2006) 1.22
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol (2010) 1.21
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood (2005) 1.19
Immunophenotyping of blood lymphocytes at birth, during childhood, and during adulthood in HIV-1-uninfected Ethiopians. Clin Immunol (2003) 1.18
Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS (2006) 1.18
In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res (2008) 1.16
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood (2005) 1.16
Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. Mol Biol Evol (2010) 1.16
Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis (2010) 1.16
Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog (2011) 1.15
Genome-wide association study implicates PARD3B-based AIDS restriction. J Infect Dis (2011) 1.15
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol (2007) 1.14